Acute myelogenous leukaemia

A/J A Jackson inbred mouse strain ALP Anti-leukoprotease ALS Amyotrophic lateral sclerosis cAMP Cyclic adenosine monophosphate also known as adenosine 3, 5 -phosphate AM Alveolar macrophage AML Acute myelogenous leukaemia AMP Adenosine monophosphate AMVN 2,2 -azobis (2,4-dimethylvaleronitrile)... 

Gemtuzumab Ozogamicin Acute myelogenous leukaemia (CD33)... 

Lee, S.T., Jang, J. H., Cheong, J. W., et al. (2002),Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype, Br. J. Haematol, 118(4), 1128-1131. 

Acute myelogenous leukaemia (AML) induction cytarabine + either dauriOrubicin or idarubicin PostindiiClion high do e cytarabine z other drugs such as etoposide bone marrow transplant... 

Ino, T., Miyazaki, H., Isogai, M., Nomura, T., Tsuzuki, M., Tsuruo, T Ezaki, K., and Hirano, M. (1994) Expression of P-glycoprotein in de-novo acute myelogenous leukaemia at initial diagnosis results of molecular and functional assays, and correlation with treatment outcome. Leukaemia 8,1492-1497. 

Vasioukhin V> Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N Ras gene in the blood plasma DNA of patients with myelodys-plastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994 86 774-9. 

Usuki K, Urabe A, Masaoka T, et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia a multicentre randomized study. Br J Haematol 2002 116 103-112. 

Muenchow N, Janka G, ErttmannR, Looft G, Bielack S, Winkler K. Increased vincristine neurotoxicity during treatment wifii itraconazole in 3 pediatric patients with acute myelogenous leukaemia. Blood(1999) 94 (Suppl 1, part 2) 234b. 

C8H11N3O4 213.193 Antineoplastic agent. Anti-HIV agent. Phase III clin. trials for acute myelogenous leukaemia (2002). The name troxacitabine refers to the (25,45)-form. 

Tzankov A, Ludescher C, Duba HC, Steinlechner M, Knapp R, Schmid T, Grunewald K, Gastl G, Stauder R (2001) Spontaneous remission in a secondary acute myelogenous leukaemia following invasive pulmonary aspergillosis. Ann Hematol 80 423 425... 

NSCLC Non-small cell lung cancer, SCLC Small cell lung cancer, SCC Squamous cell carcinoma, MM Malignant melanoma, NHL Non-Hodgkin s lymphoma, HL Hodgkin s lymphoma, ATL Adult T-cell leukaemia-lymphoma, ALL Acute lymphocytic leukaemia, AML Acute myelogenous leukaemia... 

Vrooman LM, Neuberg DS, Stevenson KE, AsseUn BL, Athale UH, Clavell L, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011 47(9) 1373-9. 

Haematoxicity, particularly pancytopenia (diminution of all formed elements in the blood), has been observed in both humans and animals following exposure to benzene [12, 13, 196, 198, 224, 242-248]. Benzene-induced pancytopenia and aplastic bone marrow indicate a greater risk to acute myelogenous leukaemia and erythroleukaemia [196]. The effect of increase in red blood cell levels of delta-aminolevulinic acid (a precursor in the haeme biosynthetic pathway) and the effect of decrease in the mean serum complement of the blood occur at benzene occupational exposure levels of 3-15 ppm, and may also have a potential significance [196]. According to a study of the hypofunction of different blood systems, disorders occur at benzene exposure rates of 2-500 ppm [3, 12, 13, 198]. Isolated cases of abnormal blood composition due to minimum exposure levels of 2-3 ppm have been reported from Italy and France [249, 250]. 

Heat production rate has been measured in polymorphonuclear granulocytes (PMN) from patients with acute myelogenous leukaemia and compared to the corresponding results obtained in a group of healthy individuals [35 ]. Patients... 

Heat production rate (P) of polymorphonuclear granulocytes from normal subjects and patients with acute myelogenous leukaemia (AML) in the acute stage and during emission. Source reference 35. 

Two patients who were treated for nodular lymphomas with chlorambucil for periods of 4 and 7 years respectively and had an excellent response, but who both terminated their clinical course with acute myelogenous leukaemia, are noted (82). It is pointed out that the spontaneous incidence of acute myelogenous leukaemia is estimated at l.S per 100,000 per year. 

Silverglied, A. J. and Schrier, S. L. (1974) Acute myelogenous leukaemia in two patients treated with azathioprine for non-malignant diseases. Amer. J. Med., 57,885. 

---